{"filing":{"accession_number":"0001493152-26-027047","cik":"0001839133","ticker":null,"company_name":"IR-Med, Inc.","form":"8-K","filing_date":"2026-06-03","report_date":null,"primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1839133/000149315226027047/form8-k.htm"},"events":[{"id":7248,"run_id":6362,"accession_number":"0001493152-26-027047","anchor_item_number":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"summary":"The filing discloses a private placement of 250,000 shares of common stock and 250,000 warrants at $0.10 per share, closing on May 31, 2026, with gross proceeds of $19,054. Item 1.01 and Item 3.02 document an unregistered equity issuance under Section 4(a)(2) and Regulation D, which is a classic dilutive issuance. The inclusion of warrant coverage (1:1 ratio) and insider participation by directors and the chairman further signals capital-raising pressure typical of small-cap companies. Item 5.02 also discloses large option grants (5.04M, 3.24M, and 2.78M shares) to executives at $0.001 exercise price, which compounds dilution.","company_name":"IR-Med, Inc.","ticker":null,"filing_date":"2026-06-03","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":4077,"accession_number":"0001493152-26-027047","item_number":null,"item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The filing discloses a private placement of 250,000 shares of common stock and 250,000 warrants at $0.10 per share, closing on May 31, 2026, with gross proceeds of $19,054. Item 1.01 and Item 3.02 document an unregistered equity issuance under Section 4(a)(2) and Regulation D, which is a classic dilutive issuance. The inclusion of warrant coverage (1:1 ratio) and insider participation by directors and the chairman further signals capital-raising pressure typical of small-cap companies. Item 5.02 also discloses large option grants (5.04M, 3.24M, and 2.78M shares) to executives at $0.001 exercise price, which compounds dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:46:07.381242+00:00","company_name":"IR-Med, Inc.","ticker":null,"filing_date":"2026-06-03"}]}